Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
Titel:
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
Auteur:
Santin, Alessandro D. Filiaci, Virginia Bellone, Stefania O’Cearbhaill, Roisin Ratner, Elena S. Mathews, Cara A. Cantuaria, Guilherme Gunderson, Camille C. Rutledge, Teresa Buttin, Barbara M. Lankes, Heather A. Birrer, Michael J.